Perspectives and Risks of Breast-Conservation Therapy for Breast Cancer

  • Dimitrios H. Roukos
  • Angelos M. Kappas
  • Niki J. Agnantis
Editorials

REFERENCES

  1. 1.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Elisaf M, Roukos DH, Briasoulis E, Michos KM, Agnantis NJ, Kappas AM. Comparing recent advances in gastric and breast cancer. Gastric Breast Cancer 2002; 1: 59–64.Google Scholar
  3. 2a.
    Morrow M, Strom EA, Bassett LW, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin 2002; 52: 277–300.PubMedCrossRefGoogle Scholar
  4. 3.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233–41.PubMedCrossRefGoogle Scholar
  5. 4.
    Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227–32.PubMedCrossRefGoogle Scholar
  6. 5.
    Morrow M. Rational local therapy for breast cancer. N Engl J Med 2002; 347: 1270–1.PubMedCrossRefGoogle Scholar
  7. 6.
    van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92: 1143–50.PubMedCrossRefGoogle Scholar
  8. 7.
    Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nikolaou N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol 2002; 20: 4015–21.PubMedCrossRefGoogle Scholar
  9. 8.
    Neuschatz AC, DiPetrillo T, Safaii H, et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 2003; 97: 30–9.PubMedCrossRefGoogle Scholar
  10. 9.
    Roukos DH, Agnantis NJ, Batsis H, Paraskevaidis E, Kappas AM. Breast-conserving surgery and risk of positive margins in breast cancer. Gastric Breast Cancer 2003;2:15–9. Available at: http://www.gastriccancer.net/Margins_abs.asp.Google Scholar
  11. 10.
    Smitt MC, Nowels KW, Zdeblich MJ, et al. The important of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 1995; 76: 259–67.PubMedCrossRefGoogle Scholar
  12. 11.
    Park C, Mitsumori M, Recht A, et al. The relationship between pathologic margin status and outcome after breast-conserving therapy. Int J Radiat Oncol Biol Phys 1998; 42: 125.Google Scholar
  13. 12.
    Cowen D, Houvenaeghel G, Bardou V-J, et al. Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys 2000; 47: 305–12.PubMedCrossRefGoogle Scholar
  14. 13.
    Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumour lymphatics. Science 2002; 296: 1883–6.PubMedCrossRefGoogle Scholar
  15. 14.
    Peterson ME, Schultz DJ, Reynolds C, et al. Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 1999; 43: 1029–35.PubMedCrossRefGoogle Scholar
  16. 15.
    National Surgical Adjuvant Breast and Bowel Project. NSABP Progress Report 2001. Pittsburgh: National Surgical Adjuvant Breast and Bowel Project, 2002:84, 94, 140.Google Scholar
  17. 16.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42.PubMedCrossRefGoogle Scholar
  18. 17.
    Dalberg K, Johansson H, Johansson U, et al. A randomized trial of long-term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy for patients with early-stage breast carcinoma treated with breast-conserving surgery. Cancer 1998; 82: 2204—11.PubMedCrossRefGoogle Scholar
  19. 18.
    Smith TE, Lee D, Turner BC, Carter B, Haffty BG. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 2000; 481: 281–9.Google Scholar
  20. 19.
    Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: 1378–87.PubMedCrossRefGoogle Scholar
  21. 20.
    Black N. Evidence-based surgery: a passing fad? World J Surg 1999; 23: 789–93.PubMedCrossRefGoogle Scholar
  22. 21.
    Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355: 1757–70.CrossRefGoogle Scholar
  23. 22.
    Kurtz JM, Jacquemier J, Amalric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990; 8: 591–8.PubMedGoogle Scholar
  24. 23.
    Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995; 196: 115–22.PubMedGoogle Scholar
  25. 24.
    van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009.PubMedCrossRefGoogle Scholar
  26. 25.
    Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566–75.PubMedCrossRefGoogle Scholar
  27. 26.
    Roukos DH, Agnantis NJ. Gene-expression profile: the future in the outcome prediction and treatment of breast cancer. Gastric Brteast Cancer 2003;2:5–8. Available at: http://www.gastriccancer.net/ Gene-Expression_abs.asp.Google Scholar
  28. 27.
    Agnantis NJ, Roukos DH. Cyclin E: a new biologic prognostic marker for breast cancer? Gastric Breast Cancer 2003;2:9–11. Available at: http://www.gastriccancer.net/Cyclin_abs.asp.Google Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Dimitrios H. Roukos
    • 1
    • 3
  • Angelos M. Kappas
    • 2
  • Niki J. Agnantis
    • 3
  1. 1.Departments of SurgeryIoannina University School of MedicineGreece
  2. 2.Departments of PathologyIoannina University School of MedicineGreece
  3. 3.Department of SurgeryIoannina University School of MedicineIoanninaGreece

Personalised recommendations